annual current liabilities:
$139.10M+$26.61M(+23.65%)Summary
- As of today (June 22, 2025), HALO annual total current liabilities is $139.10 million, with the most recent change of +$26.61 million (+23.65%) on December 31, 2024.
- During the last 3 years, HALO annual current liabilities has risen by +$21.95 million (+18.74%).
- HALO annual current liabilities is now -66.99% below its all-time high of $421.38 million, reached on December 31, 2020.
Performance
HALO Current liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly current liabilities:
$150.38M+$11.28M(+8.11%)Summary
- As of today (June 22, 2025), HALO quarterly total current liabilities is $150.38 million, with the most recent change of +$11.28 million (+8.11%) on March 31, 2025.
- Over the past year, HALO quarterly current liabilities has increased by +$18.74 million (+14.24%).
- HALO quarterly current liabilities is now -64.31% below its all-time high of $421.38 million, reached on December 31, 2020.
Performance
HALO quarterly current liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Current liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
HALO Current liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +23.6% | +14.2% |
| 3 y3 years | +18.7% | +34.6% |
| 5 y5 years | +62.4% | +258.0% |
HALO Current liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +23.6% | -24.6% | +63.6% |
| 5 y | 5-year | -67.0% | +62.4% | -64.3% | +476.8% |
| alltime | all time | -67.0% | >+9999.0% | -64.3% | >+9999.0% |
HALO Current liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $150.38M(+8.1%) |
| Dec 2024 | $139.10M(+23.7%) | $139.10M(+27.8%) |
| Sep 2024 | - | $108.81M(-18.4%) |
| Jun 2024 | - | $133.36M(+1.3%) |
| Mar 2024 | - | $131.64M(+17.0%) |
| Dec 2023 | $112.49M(-14.0%) | $112.49M(-2.3%) |
| Sep 2023 | - | $115.19M(-1.0%) |
| Jun 2023 | - | $116.39M(+26.6%) |
| Mar 2023 | - | $91.92M(-29.7%) |
| Dec 2022 | $130.79M(+11.6%) | $130.79M(+19.6%) |
| Sep 2022 | - | $109.38M(-45.2%) |
| Jun 2022 | - | $199.51M(+78.6%) |
| Mar 2022 | - | $111.69M(-4.7%) |
| Dec 2021 | $117.15M(-72.2%) | $117.15M(+3.5%) |
| Sep 2021 | - | $113.15M(-1.0%) |
| Jun 2021 | - | $114.25M(+6.4%) |
| Mar 2021 | - | $107.42M(-74.5%) |
| Dec 2020 | $421.38M(+392.1%) | $421.38M(+1462.1%) |
| Sep 2020 | - | $26.98M(+3.5%) |
| Jun 2020 | - | $26.07M(-37.9%) |
| Mar 2020 | - | $42.00M(-51.0%) |
| Dec 2019 | $85.64M(-42.7%) | $85.64M(-20.7%) |
| Sep 2019 | - | $108.04M(-20.2%) |
| Jun 2019 | - | $135.42M(-2.3%) |
| Mar 2019 | - | $138.66M(-7.2%) |
| Dec 2018 | $149.36M(+13.7%) | $149.36M(+7.4%) |
| Sep 2018 | - | $139.12M(+5.1%) |
| Jun 2018 | - | $132.43M(+11.1%) |
| Mar 2018 | - | $119.22M(-9.2%) |
| Dec 2017 | $131.33M(+140.6%) | $131.33M(+28.7%) |
| Sep 2017 | - | $102.05M(+23.5%) |
| Jun 2017 | - | $82.61M(+33.9%) |
| Mar 2017 | - | $61.71M(+13.0%) |
| Dec 2016 | $54.59M(-12.6%) | $54.59M(+3.7%) |
| Sep 2016 | - | $52.66M(+35.4%) |
| Jun 2016 | - | $38.88M(-39.5%) |
| Mar 2016 | - | $64.22M(+2.8%) |
| Dec 2015 | $62.46M(+156.7%) | $62.46M(+39.3%) |
| Sep 2015 | - | $44.85M(+28.0%) |
| Jun 2015 | - | $35.04M(+33.7%) |
| Mar 2015 | - | $26.21M(+7.7%) |
| Dec 2014 | $24.33M(-2.3%) | $24.33M(-29.7%) |
| Sep 2014 | - | $34.59M(+9.1%) |
| Jun 2014 | - | $31.72M(-12.8%) |
| Mar 2014 | - | $36.36M(+46.0%) |
| Dec 2013 | $24.90M | $24.90M(-37.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2013 | - | $39.62M(+20.7%) |
| Jun 2013 | - | $32.83M(+66.2%) |
| Mar 2013 | - | $19.75M(+4.2%) |
| Dec 2012 | $18.95M(+9.5%) | $18.95M(-9.9%) |
| Sep 2012 | - | $21.04M(+30.3%) |
| Jun 2012 | - | $16.15M(-3.2%) |
| Mar 2012 | - | $16.68M(-3.6%) |
| Dec 2011 | $17.30M(+12.8%) | $17.30M(+25.4%) |
| Sep 2011 | - | $13.79M(-56.3%) |
| Jun 2011 | - | $31.54M(+150.3%) |
| Mar 2011 | - | $12.60M(-17.9%) |
| Dec 2010 | $15.34M(+6.6%) | $15.34M(+30.2%) |
| Sep 2010 | - | $11.78M(+6.5%) |
| Jun 2010 | - | $11.06M(-19.6%) |
| Mar 2010 | - | $13.76M(-4.4%) |
| Dec 2009 | $14.40M(+1.3%) | $14.40M(-9.0%) |
| Sep 2009 | - | $15.81M(+4.3%) |
| Jun 2009 | - | $15.17M(+13.8%) |
| Mar 2009 | - | $13.33M(-6.2%) |
| Dec 2008 | $14.22M(+60.4%) | $14.22M(+28.5%) |
| Sep 2008 | - | $11.06M(+17.6%) |
| Jun 2008 | - | $9.41M(-2.0%) |
| Mar 2008 | - | $9.60M(+8.3%) |
| Dec 2007 | $8.86M(+108.5%) | $8.86M(+7.3%) |
| Sep 2007 | - | $8.26M(+37.7%) |
| Jun 2007 | - | $6.00M(+16.4%) |
| Mar 2007 | - | $5.16M(+21.3%) |
| Dec 2006 | $4.25M(+84.5%) | $4.25M(+54.2%) |
| Sep 2006 | - | $2.76M(+13.7%) |
| Jun 2006 | - | $2.43M(-9.9%) |
| Mar 2006 | - | $2.69M(+16.9%) |
| Dec 2005 | $2.30M(+45.8%) | $2.30M(+27.2%) |
| Sep 2005 | - | $1.81M(+5.6%) |
| Jun 2005 | - | $1.72M(-11.0%) |
| Mar 2005 | - | $1.93M(+22.1%) |
| Dec 2004 | $1.58M(>+9900.0%) | $1.58M(-20.7%) |
| Sep 2004 | - | $1.99M(+53.9%) |
| Jun 2004 | - | $1.29M(+67.3%) |
| Mar 2004 | - | $773.20K(>+9900.0%) |
| Sep 2003 | - | $4800.00(0.0%) |
| Jun 2003 | - | $4800.00(-66.7%) |
| Mar 2003 | - | $14.40K(+213.0%) |
| Sep 2002 | - | $4600.00(+39.4%) |
| Jun 2002 | - | $3300.00(-35.3%) |
| Mar 2002 | - | $5100.00 |
| Dec 2001 | $3300.00 | - |
FAQ
- What is Halozyme Therapeutics annual total current liabilities?
- What is the all time high annual current liabilities for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual current liabilities year-on-year change?
- What is Halozyme Therapeutics quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly current liabilities year-on-year change?
What is Halozyme Therapeutics annual total current liabilities?
The current annual current liabilities of HALO is $139.10M
What is the all time high annual current liabilities for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual total current liabilities is $421.38M
What is Halozyme Therapeutics annual current liabilities year-on-year change?
Over the past year, HALO annual total current liabilities has changed by +$26.61M (+23.65%)
What is Halozyme Therapeutics quarterly total current liabilities?
The current quarterly current liabilities of HALO is $150.38M
What is the all time high quarterly current liabilities for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly total current liabilities is $421.38M
What is Halozyme Therapeutics quarterly current liabilities year-on-year change?
Over the past year, HALO quarterly total current liabilities has changed by +$18.74M (+14.24%)